Home › NDC Lookup › RxCUI directory › RxCUI 1741739

Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet [Odefse... — RxCUI 1741739

Name: Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet [O… (RxCUI 1741739)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1741739 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1741739

Official nameEmtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet [Odefsey]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asOdefsey (emtricitabine 200 MG / rilpivirine 25 MG (as rilpivirine HCl 27.5 MG) / tenofovir alafenamide 25 MG (as tenofovir alafenamide fumarate 28 MG)) Oral Tablet; ODEFSEY 200 MG / 25 MG/ 25 MG Oral Tablet

FDA products mapped1

Package NDCs mapped1

Reported Medicaid activity (SDUD)45,852 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Emtricitabine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Emtricitabine doesn't cure HIV, but it's an important part of keeping the virus under control. It works by blocking an enzyme HIV needs to make copies of itself. When it's used alo...
What exactly does emtricitabine do — does it cure HIV?
Please don't stop without talking to your doctor first. If you also have hepatitis B, stopping emtricitabine can trigger a sudden, severe flare of hepatitis B — sometimes serious e...
Can I stop taking emtricitabine if I feel fine or if I also have hepatitis B?

📖 Read our full Emtricitabine guide →

🕸️ Concept Web — How Emtricitabine 200 MG / rilpivirine 25 MG / tenof... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet [Odefsey] RxCUI 1741739 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 4

The active substance itself — no strength, form, or brand attached yet.
- Emtricitabine 276237 IN
- Rilpivirine 1102270 IN
- Tenofovir alafenamide 1721603 IN
- Emtricitabine / rilpivirine / tenofovir alafenamide 1727492 MIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Odefsey 1741734 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet 1741732 SCDF
- Emtricitabine / rilpivirine / tenofovir alafenamide Oral Product 1741730 SCDG
- Emtricitabine / rilpivirine / tenofovir alafenamide Pill 1741731 SCDG
- Emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet [Odefsey] 1741736 SBDF
- Odefsey Oral Product 1741737 SBDG
- Odefsey Pill 1741738 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 5

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet 1741733 SCD
- Emtricitabine 200 MG 406016 SCDC
- Rilpivirine 25 MG 1102271 SCDC
- Tenofovir alafenamide 25 MG 1741729 SCDC
- Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG [Odefsey] 1741735 SBDC

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet SCD · 1741733
Emtricitabine 200 MG SCDC · 406016
Rilpivirine 25 MG SCDC · 1102271
Tenofovir alafenamide 25 MG SCDC · 1741729
Emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet SCDF · 1741732
Emtricitabine / rilpivirine / tenofovir alafenamide Oral Product SCDG · 1741730
Emtricitabine / rilpivirine / tenofovir alafenamide Pill SCDG · 1741731

Brand-Name Concepts

Emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG [Odefsey] SBDC · 1741735
Emtricitabine / rilpivirine / tenofovir alafenamide Oral Tablet [Odefsey] SBDF · 1741736
Odefsey Oral Product SBDG · 1741737
Odefsey Pill SBDG · 1741738
Odefsey BN · 1741734

📦 FDA Products & Package NDCs

1 product · 1 package NDC

1 package NDC map to RxCUI 1741739 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
61958-2101-01	30 TABLET in 1 BOTTLE, PLASTIC (61958-2101-1)	ODEFSEY	Gilead Sciences, Inc.	2016-03-01

Observed labelers: Gilead Sciences, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ea · median

$130.3850

Range $130.3850–$130.3850 · middle 50% $130.3850–$130.3850 · 1 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.